4267 Noninvasive hybrid ultrasound and photoacoustic imaging for the assessment of liver fibrosis

Autor: Laith Riyadh Sultan, Mrigendra Karmacharya, Julia D’Souza, Brooke Kirkham, Angela K Brice, Andrew KW Wood, Stephen Hunt, Chandra Sehgal

Publikováno v: Journal of Clinical and Translational Science, Vol 4, Pp 110-111 (2020)

OBJECTIVES/GOALS: The detection of liver fibrotic changes at an early and reversible stage is essential to prevent its progression to end-stage cirrhosis and hepatocellular carcinoma. Liver biopsy, which is the current gold standard for fibrosis asse

Externí odkaz: https://doaj.org/article/7a19a20b657e42d2b9e5b6e9f7f68e05

4267 Noninvasive hybrid ultrasound and photoacoustic imaging for the assessment of liver fibrosis

Autor: Angela K Brice, Julia C D'Souza, Chandra M. Sehgal, Laith R. Sultan, Brooke M Kirkham, Andrew Kw Wood, Stephen J. Hunt, Mrigendra B. Karmacharya

Publikováno v: Journal of Clinical and Translational Science. 4:110-111

OBJECTIVES/GOALS: The detection of liver fibrotic changes at an early and reversible stage is essential to prevent its progression to end-stage cirrhosis and hepatocellular carcinoma. Liver biopsy, which is the current gold standard for fibrosis asse

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::18e169b3132c87420bd6e9a36ec50afa
https://doi.org/10.1017/cts.2020.338

FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer.

Autor: Caligiuri M; Forma Therapeutics, Inc, 300 N Beacon St, Watertown, MA, 02472, USA., Williams GL; Forma Therapeutics, Inc, 300 N Beacon St, Watertown, MA, 02472, USA., Castro J; Forma Therapeutics, Inc, 300 N Beacon St, Watertown, MA, 02472, USA., Battalagine L; Forma Therapeutics, Inc, 300 N Beacon St, Watertown, MA, 02472, USA., Wilker E; Forma Therapeutics, Inc, 300 N Beacon St, Watertown, MA, 02472, USA., Yao L; Forma Therapeutics, Inc, 300 N Beacon St, Watertown, MA, 02472, USA., Schiller S; Forma Therapeutics, Inc, 300 N Beacon St, Watertown, MA, 02472, USA., Toms A; Forma Therapeutics, Inc, 300 N Beacon St, Watertown, MA, 02472, USA., Li P; Forma Therapeutics, Inc, 300 N Beacon St, Watertown, MA, 02472, USA., Pardo E; Forma Therapeutics, Inc, 300 N Beacon St, Watertown, MA, 02472, USA., Graves B; Forma Therapeutics, Inc, 300 N Beacon St, Watertown, MA, 02472, USA., Azofeifa J; Arpeggio Bio, Boulder, CO, USA., Chicas A; Forma Therapeutics, Inc, 300 N Beacon St, Watertown, MA, 02472, USA., Herbertz T; Forma Therapeutics, Inc, 300 N Beacon St, Watertown, MA, 02472, USA., Lai M; Arpeggio Bio, Boulder, CO, USA., Basken J; Arpeggio Bio, Boulder, CO, USA., Wood KW; Forma Therapeutics, Inc, 300 N Beacon St, Watertown, MA, 02472, USA., Xu Q; Forma Therapeutics, Inc, 300 N Beacon St, Watertown, MA, 02472, USA., Guichard SM; Forma Therapeutics, Inc, 300 N Beacon St, Watertown, MA, 02472, USA. sguichard@formatherapeutics.com.

Publikováno v: Targeted oncology [Target Oncol] 2023 Mar; Vol. 18 (2), pp. 269-285. Date of Electronic Publication: 2023 Feb 24.

Erratum to: Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.

Autor: Hu Z; Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University, 3303 SW Bond Ave., CH13B, Portland, OR, 97239, USA., Mao JH; Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, 94127, USA., Curtis C; Department of Medicine, Division of Oncology and Department of Genetics, Stanford University School of Medicine, Stanford, CA, 94305, USA., Huang G; Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University, 3303 SW Bond Ave., CH13B, Portland, OR, 97239, USA., Gu S; Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University, 3303 SW Bond Ave., CH13B, Portland, OR, 97239, USA., Heiser L; Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University, 3303 SW Bond Ave., CH13B, Portland, OR, 97239, USA., Lenburg ME; Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA, 02215, USA., Korkola JE; Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University, 3303 SW Bond Ave., CH13B, Portland, OR, 97239, USA., Bayani N; Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, 94127, USA., Samarajiwa S; MRC Cancer Unit, University of Cambridge, Cambridge, CB2 0XZ, UK., Seoane JA; Department of Medicine, Division of Oncology and Department of Genetics, Stanford University School of Medicine, Stanford, CA, 94305, USA., Dane MA; Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University, 3303 SW Bond Ave., CH13B, Portland, OR, 97239, USA., Esch A; Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University, 3303 SW Bond Ave., CH13B, Portland, OR, 97239, USA., Feiler HS; Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University, 3303 SW Bond Ave., CH13B, Portland, OR, 97239, USA., Wang NJ; Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University, 3303 SW Bond Ave., CH13B, Portland, OR, 97239, USA., Hardwicke MA; GlaxoSmithKline, Collegeville, PA, 19425, USA., Laquerre S; GlaxoSmithKline, Collegeville, PA, 19425, USA., Jackson J; GlaxoSmithKline, Collegeville, PA, 19425, USA., Wood KW; Cytokinetics, Inc., South San Francisco, CA, 94080, USA., Weber B; GlaxoSmithKline, Collegeville, PA, 19425, USA., Spellman PT; Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University, 3303 SW Bond Ave., CH13B, Portland, OR, 97239, USA., Aparicio S; Molecular Oncology, BC Cancer Research Centre, Vancouver, Canada., Wooster R; GlaxoSmithKline, Collegeville, PA, 19425, USA., Caldas C; Cancer Research UK, Cambridge Institute, Cambridge, UK. carlos.caldas@cancer.org.uk., Gray JW; Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University, 3303 SW Bond Ave., CH13B, Portland, OR, 97239, USA. Grayjo@ohsu.edu.

Publikováno v: Breast cancer research : BCR [Breast Cancer Res] 2017 Feb 09; Vol. 19 (1), pp. 17. Date of Electronic Publication: 2017 Feb 09.

Subtype and pathway specific responses to anticancer compounds in breast cancer.

Autor: Heiser LM; Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA., Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, Jakkula L, Korkola JE, Durinck S, Pepin F, Guan Y, Purdom E, Neuvial P, Bengtsson H, Wood KW, Smith PG, Vassilev LT, Hennessy BT, Greshock J, Bachman KE, Hardwicke MA, Park JW, Marton LJ, Wolf DM, Collisson EA, Neve RM, Mills GB, Speed TP, Feiler HS, Wooster RF, Haussler D, Stuart JM, Gray JW, Spellman PT

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2012 Feb 21; Vol. 109 (8), pp. 2724-9. Date of Electronic Publication: 2011 Oct 14.